Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

FDA's Richard Pazdur to Retire, Triggering Leadership Upheaval

FDA's Richard Pazdur to Retire, Triggering Leadership Upheaval

Richard Pazdur, the recently appointed director of the FDA's Center for Drug Evaluation and Research (CDER), has filed paperwork to retire at the end of December, just weeks after accepting the role. This sudden development adds to the ongoing leadership turmoil at the agency and raises concerns about regulatory stability in the pharmaceutical industry.

NoahAI News12/3/2025
Imvax's Glioblastoma Immunotherapy Shows Promise Despite Endpoint Miss

Imvax's Glioblastoma Immunotherapy Shows Promise Despite Endpoint Miss

Imvax, a Philadelphia-based biotech company, is moving forward with plans to approach the FDA regarding its investigational glioblastoma immunotherapy, IGV-001, despite missing the primary endpoint in a recent Phase IIb trial. The company's decision highlights the potential impact of the treatment on overall survival rates and underscores the urgent need for new therapies in this challenging area of oncology.

NoahAI News12/3/2025
Roche's Comeback in Alzheimer's Marks New Era in Treatment Landscape

Roche's Comeback in Alzheimer's Marks New Era in Treatment Landscape

Roche's recent announcement of a successful Phase I/II trial for its antibody trontinemab has signaled a potential renaissance in Alzheimer's disease treatment, marking the Swiss pharmaceutical giant's return to the forefront of neurodegenerative research. This development comes years after the controversial approval and subsequent withdrawal of Biogen's Aduhelm, which had initially sent shockwaves through the industry.

NoahAI News12/3/2025
Roche's Trontinemab Shows Promise in Alzheimer's Disease, Marking Company's Return to the Field

Roche's Trontinemab Shows Promise in Alzheimer's Disease, Marking Company's Return to the Field

Roche, the Swiss pharmaceutical giant, has made a significant comeback in the Alzheimer's disease space with its next-generation antibody, trontinemab. The company presented promising results from its ongoing Phase I/II Brainshuttle AD study at the 2025 Clinical Trials on Alzheimer's Disease (CTAD) meeting, showcasing the drug's potential in clearing amyloid plaques and possibly affecting tau protein accumulation in the brain.

NoahAI News12/3/2025
Boston Scientific Expands Pulsed Field Ablation Portfolio with European Approval for Farapoint Catheter

Boston Scientific Expands Pulsed Field Ablation Portfolio with European Approval for Farapoint Catheter

Boston Scientific has secured CE Mark approval for its Farapoint focal catheter, the latest addition to its pulsed field ablation (PFA) portfolio. This development marks a significant expansion of the company's Farapulse platform for treating irregular heart rhythms, now including the treatment of right atrial flutter.

NoahAI News12/3/2025
Cleveland Diagnostics Secures FDA Approval for Novel Prostate Cancer Test

Cleveland Diagnostics Secures FDA Approval for Novel Prostate Cancer Test

Cleveland Diagnostics has received Food and Drug Administration (FDA) approval for its innovative prostate cancer test, IsoPSA, marking a significant advancement in prostate cancer diagnostics. The test, designed for men aged 50 and older with elevated prostate-specific antigen (PSA) levels, aims to improve risk assessment and reduce unnecessary biopsies.

NoahAI News12/3/2025
Janux Therapeutics' JANX007 Data Update: Mixed Results and Market Reaction

Janux Therapeutics' JANX007 Data Update: Mixed Results and Market Reaction

Janux Therapeutics has released new data for its investigational T-cell engager JANX007, currently in phase 1a/1b trials for advanced castration-resistant prostate cancer. The update, while showing promise, has led to a significant drop in the company's stock price.

NoahAI News12/3/2025
Roche's Rapid Whooping Cough Test Gains Regulatory Approval Amid Global Surge in Cases

Roche's Rapid Whooping Cough Test Gains Regulatory Approval Amid Global Surge in Cases

Roche has secured regulatory approvals in both the United States and Europe for its innovative point-of-care test for whooping cough, marking a significant advancement in diagnostic capabilities as cases surge worldwide. The test, designed for use in various healthcare settings, promises to deliver results in under 15 minutes, potentially revolutionizing the diagnosis and management of this highly contagious respiratory disease.

NoahAI News12/3/2025
Pharmaceutical Industry Roundup: Janux Setback, FDA Reviews, and Leadership Changes

Pharmaceutical Industry Roundup: Janux Setback, FDA Reviews, and Leadership Changes

Janux Therapeutics experienced a significant stock price drop of nearly 50% following the release of new early-stage results for their "masked" T cell engager, JANX007, in advanced prostate cancer treatment. The latest data revealed a response rate of 30% among 27 evaluable patients, a decrease from the 50% response rate reported in December. This decline has raised concerns among investors, although some analysts, such as William Blair's Matt Phipps, suggest the selloff may be an "overreaction."

NoahAI News12/3/2025
Pharmaceutical Industry Invests Heavily in US Manufacturing Amid Onshoring Boom

Pharmaceutical Industry Invests Heavily in US Manufacturing Amid Onshoring Boom

Major pharmaceutical companies have pledged over $370 billion in investments for US projects over the next five years, according to a recent market trend report by DPR Construction. This surge in domestic investment comes as the industry responds to trade policies and regulatory initiatives aimed at boosting US pharmaceutical manufacturing and strengthening the supply chain.

NoahAI News12/3/2025
Aledade Secures $500M Credit Facility to Accelerate Value-Based Care Expansion

Aledade Secures $500M Credit Facility to Accelerate Value-Based Care Expansion

Value-based care enablement company Aledade has closed a $500 million senior secured credit facility, marking a significant milestone in its mission to transform primary care in the United States. The deal, led by Ares Credit funds, provides Aledade with substantial financial flexibility to support its rapid growth and scale its operations across the country.

NoahAI News12/3/2025
Curative Secures $150M in Series B Funding, Achieves Unicorn Status

Curative Secures $150M in Series B Funding, Achieves Unicorn Status

Technology-enabled health plan provider Curative has successfully raised $150 million in a Series B funding round, propelling the company to a valuation of $1.275 billion. This significant investment underscores growing interest in Curative's innovative health insurance model, which offers plans with zero out-of-pocket costs for members.

NoahAI News12/3/2025
«1...678...67»